Mantle cell lymphoma
Conditions
Interventions
Experimental group:Zuberitamb plus bendamustine or high-dose cytarabine
Sponsors
Second Affliated Hospital of Army Medical University, PLA
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Subjects voluntarily join this study and sign the informed consent form; 2. Age>=18 years old, and = 3 months; 9. Cardiac color ultrasound: left ventricular ejection fraction >=50%; 10. Subjects voluntarily joined this study, signed the informed consent form, had good compliance, and cooperated with follow-up.
Exclusion criteria
Exclusion criteria: 1. The pathology is blast-like or pleomorphic variant MCL; 2. Patients with TP53 mutation or CDNK2A deletion confirmed by immunohistochemistry or FISH; 3. Received systemic or local therapy including chemotherapy within three weeks prior to enrollment; 4. Accompanied by other malignant tumors that require treatment or affect survival; 5. Clinically significant cardiac disease; 6. Patients who underwent major surgery within 4 weeks before enrollment; 7. Abnormal digestive tract function, such as gastric resection, intestinal resection, inflammatory bowel disease, etc.; 8. Chronic or active infectious diseases requiring systemic antibiotic, antifungal or antiviral therapy; 9. Concomitant treatment with anticoagulant drugs, or strong CYP3A4/5 inhibitors/inducers; 10. HBsAg positive; or HBsAg-negative but HBcAb-positive and HBV-DNA copy number above the upper limit of normal for detection; HCV antibody positive, and HCV-RNA copy number higher than the normal limit of the detection value; 11. HIV-infected people; 12. Central nervous system involvement; 13. Other concurrent and uncontrolled medical conditions that, in the opinion of the investigator, will affect the subject's participation in the study. Psychiatric patients or other subjects with known or suspected inability to fully comply with the study protocol; 14. Subjects judged by the investigator to be unsuitable to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall response rate;Progression free survival;Event free survival;Duration of response;Overall survival;Safety;Treatment model and corresponding patient demographic and clinical characteristics; | — |
Countries
China
Contacts
Public ContactXi Zhang
Second Affliated Hospital of Army Medical University, PLA
Outcome results
None listed